Compare RVLV & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVLV | MPLT |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2018 | 2025 |
| Metric | RVLV | MPLT |
|---|---|---|
| Price | $23.29 | $11.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | $29.73 | ★ $32.67 |
| AVG Volume (30 Days) | 906.2K | ★ 1.3M |
| Earning Date | 05-05-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.64 | ★ 82.39 |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $1,225,682,000.00 | N/A |
| Revenue This Year | $10.96 | N/A |
| Revenue Next Year | $8.01 | N/A |
| P/E Ratio | $50.30 | ★ N/A |
| Revenue Growth | ★ 8.48 | N/A |
| 52 Week Low | $17.35 | $9.10 |
| 52 Week High | $31.68 | $40.43 |
| Indicator | RVLV | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 43.03 | 28.79 |
| Support Level | $21.13 | $10.83 |
| Resistance Level | $26.97 | $20.20 |
| Average True Range (ATR) | 0.97 | 1.12 |
| MACD | -0.35 | 0.18 |
| Stochastic Oscillator | 7.92 | 13.17 |
Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.